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CaspaseCardiovascular disease is the leading cause of death in the U.S. and other developed countries. Metabolic
syndrome, including obesity, diabetes/insulin resistance, hypertension and dyslipidemia is a major threat for
public health in the modern society. It is well established that metabolic syndrome contributes to the develop-
ment of cardiovascular disease collective called as cardiometabolic disease. Despite documented studies in the
research ﬁeld of cardiometabolic disease, the underlying mechanisms are far from clear. Proteases are enzymes
that break down proteins, many ofwhich have been implicated in various diseases including cardiac disease.Ma-
trixmetalloproteinase (MMP), calpain, cathepsin and caspase are among themajor proteases involved in cardiac
remodeling. Recent studies have also implicatedproteases in the pathogenesis of cardiometabolic disease. Elevat-
ed expression and activities of proteases in atherosclerosis, coronary heart disease, obesity/insulin-associated
heart disease as well as hypertensive heart disease have been documented. Furthermore, transgenic animals
that are deﬁcient in or over-express proteases allow scientists to understand the causal relationship between
proteases and cardiometabolic disease. Mechanistically, MMPs and cathepsins exert their effect on cardiometa-
bolic diseasesmainly throughmodifying the extracellularmatrix. However,MMPand cathepsin are also reported
to affect intracellular proteins, by which they contribute to the development of cardiometabolic diseases. On the
other hand, activation of calpain and caspases has been shown to inﬂuence intracellular signaling cascade includ-
ing the NF-κB and apoptosis pathways. Clinically, proteases are reported to function as biomarkers of cardiomet-
abolic diseases.More importantly, the inhibitors of proteases are creditedwith beneﬁcial cardiometabolic proﬁle,
although the exact molecular mechanisms underlying these salutary effects are still under investigation. A better
understanding of the role of MMPs, cathepsins, calpains and caspases in cardiometabolic diseases process may
yield novel therapeutic targets for treating or controlling these diseases. This article is part of a Special Issue
entitled: Autophagy and protein quality control in cardiometabolic diseases.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Metabolic syndrome, a cluster of metabolic risk factors including
obesity, diabetes/insulin resistance, hypertension as well as dyslipid-
emia, has been identiﬁed as a multiplex risk factor for cardiovascular
disease [1,2]. Although the diagnostic criteria for metabolic syndrome
are still under debate, it is widely accepted that individuals with meta-
bolic syndrome are at high risk for cardiovascular disease [3]. Cardiovas-
cular disorders associated with metabolic syndrome are referred to as
cardiometabolic diseases. Cardiometabolic diseases are multifactorial
diseaseswith the involvement of a number of different factors including
genetic, diets, lifestyle and living environment. Cardiac remodeling,y and protein quality control in
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wyo.edu (S. Nair).coronary heart disease, even heart failure could result from metabolic
syndrome. Along with the increased rates of obesity, diabetes and
hypertension in the past decades, there has been an increase in the
incidence of cardiometabolic diseases [4,5]. Thus, recent research has
targeted cardiometabolic diseases, with an aim to understand the
pathogenesis of the disease and ﬁnd potential clinical interventions to
beneﬁt subjects afﬂicted with these diseases. Recently, proteases have
been implicated in the development and treatment of various disorders,
especially cardiovascular disease. Given the increasing incidence of
cardiometabolic diseases as well as the emerging role of proteases,
this review summarizes the roles of major proteases including matrix
metalloproteinase (MMP), calpain, cathepsin and caspase in cardiomet-
abolic diseases.
2. Proteases
Proteins are the critical components for organisms and are involved in
virtually all cellular functions. Besides protein production, thedegradation
of proteins is also important, as this is the way to recycle dysfunctional/
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Proteases are enzymes that perform protein catabolism by hydrolyzing
peptide bonds that connects the amino acids to form the protein. To
date, at least 500–600 proteases have been identiﬁed by using bioinfor-
matic analysis [6]. Proteases are classiﬁed as serine, cysteine or threonine
proteases, or as aspartic, -matrix metalloprotease and glutamic proteases
based on their site of action [7]. Besides their traditional roles in protein
turnover, proteases have been recently recognized as key-signaling mol-
ecules that participate in a number of vital physiological and pathological
processes. The extracellular and intracellular proteases including matrix
metalloproteinase (MMP), calpain, cathepsin and caspase are among
the most extensively studied ones with respect to cardiovascular disease
and remodeling. Research from our laboratory has focused on investigat-
ing the role of the cysteine proteinase cathepsin K in cardiometabolic dis-
eases, including obesity, insulin resistance and hypertension-associated
cardiac disease. Although emerging studies have shown the importance
of proteases in cardiometabolic diseases, there are still someuncertainties
remaining, and there is a paucity of review articles addressing the critical
effects of proteases in cardiometabolic disease. Therefore, this review fo-
cuses on the role of proteases in the etiopathogenesis of cardiometabolic
disease and attempts at addressing the potential molecular mechanisms
involved in the process. To begin with, we shall brieﬂy discuss the salient
features of the variousproteases that havedocumented role in cardiomet-
abolic disease and subsequently address the role of each of these prote-
ases in various disease conditions. In the subsequent section we shall
address the potential clinical relevance of proteases and avenues to
harness them in the clinical setting, followed by a brief discussion on
the future research questions which would further our understanding of
the role of proteases in cardiometabolic disorders.2.1. MMPs
MMPs are a class of metal-linked zinc-dependent proteases, whose
biological activity requires calcium. MMPs cleave internal peptide
bonds of proteins to degrade extracellular matrix (ECM). The MMP fam-
ily is further classiﬁed as collagenases, gelatinases, stromelysins, elastases
andmembrane-typeMMPs based on their enzyme characteristics. Colla-
genases, which include MMP-1, -8, and -13 cleave interstitial collagens I,
II and III at speciﬁc sites and also cleave other ECM molecules such
as gelatin and ﬁbronectin. Collagen fragments are then degraded by
gelatinases, which include MMP-2 and -9. Stromelysins, including
MMP-3, -10 and -11 are responsible for gelatin, laminin and ﬁbronectin
degradation. Elastases, which includeMMP-2, -9 and -12, degrade elastin
in arterial wall [8,9]. Membrane-type (MT)-MMPs are involved in the
cleavage of types-I, -II and -III collagens and other components of ECM,
which also activate proMMP to MMP [10]. The remarkable overlap in
the activity of MMPs' and the preferred substrate despite their different
protein structures, suggests redundancy. MMPs are synthesized as a
proenzyme form followed by the hydrolysis of the zinc-cysteine bond
to the mature form [11]. Vascular wall smooth muscle cells, endothelial
cells, monocytes, macrophages, and T-cells have been shown to secrete
MMPs [11]. The expression of MMP proenzymes is highly regulated by
transcriptional mechanisms. Cytokines such as tumor necrosis factor-α
(TNF-α) and interleukins are potent stimulants of theMMPproenzymes.
Platelet-derived growth factor (PDGF) and CD40 ligands are reported to
enhance MMP production as well [12]. In addition to regulation at
the transcriptional level, the activity of MMP is elevated by oxygen free
radicals, thrombin, chymase and angiotensin-converting enzyme (ACE)
at post-transcriptional level [13]. Conversely, nature has designed endog-
enous MMP inhibitors [tissue inhibitors of metalloproteinases (TIMPs)]
to counter-balance MMP activity. Four members of TIMP family are
currently known, which include TIMP-1 to -4. TIMP-1 inhibits MMP-1,
-3, -7 and -9. TIMP-2 inhibits MMP-2, whereas TIMP-3 is reported to
decrease activities of MMP-2 and -9. TIMP-4 on the other hand inhibits
MT-MMP and MMP-2 activity [14]. The exogenous inhibitors to MMPs,such as the tetracycline family of antibiotics are artiﬁcial MMP inhibitors
that can blunt the activity of MMPs [15].
2.2. Calpains
The calcium ion-dependent papain-like protease (calpain) is a
group of calcium-dependent, non-lysosomal neutral cysteine proteases
[16,17]. So far, at least 16 calpains have been identiﬁed, most of them,
including calpain 1, requiring micromolar concentrations of calcium
for activity. Interestingly, calpain 2 requires millimolar calcium concen-
trations. Calpains are ubiquitously expressed on all types of cells [18].
However, some calpains, such as calpain 3, which is a skeletal muscle-
speciﬁc protease are tissue speciﬁc [19]. Localized in cytosol, calpains
mainly target intracellular proteins. A large number of proteins have
been reported to be degraded by calpains, which include, but not limit-
ed to Bax [20,21], calcineurin [22], caspases [23], calmodulin-protein
kinase [24], G protein [25], IΚB [26,27], p53 [28,29] and protein kinase C
(PKC) [30,31]. Although the amino acid sequences targeted by calpains
are ill-deﬁned, it is widely accepted that amino acid sequence rich in pro-
line, glutamic acid, serine and threonine elevates calpain-binding and
calpain-dependent proteolysis [32]. Calpains are primarily produced
and localized in the cytosol as proenzymes, which are then activated
by intracellular calcium inﬂux. Calcium binding relieves restrictions
that are enforced by domain interactions and thus leads to activation of
calpains [16]. Additionally, calpains are activated through direct phos-
phorylation at serine 50 by extracellular signal-regulated kinases (Erk)
even without cytosolic calcium ﬂux [33]. Calpastatin, the endogenous
inhibitor of calpain tightly regulates the activity of calpains 1 and 2. The
inhibitory effect is achieved by reversibly binding of calpastatin domains
to calpain domains. Calpain activity can be inhibited through post-
translational modiﬁcation of phosphorylation as well [16]. In addition
to the endogenous inhibitors, exogenous inhibitors of calpain, such as
calpeptin have also been designed and characterized [34]. Interestingly,
recent studies have shown that calpains are also secreted by a variety of
cells (endothelial cells, lymphocytes, chondrocytes and osteoblasts) to
extracellular space of tissues, which suggests a potential role of calpain
in ECM degradation [35,36].
2.3. Cathepsins
Cathepsins are a family of lysosomal proteases that were originally
found in the gastric juice. So far, 19 cathepsins have been identiﬁed in
mice [37]. They are classiﬁed into serine, aspartic and cysteine cathep-
sins according to the different catalytic activities. Cathepsins A and G
are serine cathepsins, cathepsins D and E are aspartic cathepsins,
whereas other cathepsins are cysteinyl cathepsins [38]. Although ca-
thepsins were initially thought to function in acidic environment only,
recent studies have found that they can be activated in neutral environ-
ment including cytosol [39,40], nucleus [41] and even secretory vesicles
[42,43] as well. Similar to calpains, some cathepsins show tissue and
cell-speciﬁc expression. For example, cathepsin K is highly expressed
on bone tissue, especially the osteoclasts [44] whereas cathepsin S
is primarily expressed on immune cells [45]. UnlikeMMPs and calpains,
cathepsins own a broad range of substrates that include almost all intra-
cellular and extracellular proteins. Nonetheless, cathepsins prefer to
degrade speciﬁc proteins, and therefore are implicated in speciﬁc phys-
iologic process, including protein turnover in bone and cartilage [46],
neuropeptide and hormone processing [47], antigen presentation [48]
and apoptosis [49]. Recent studies conﬁrm that cathepsins are synthe-
sized as pro-cathepsins with an N-terminal signal peptide targeting ER
proteins, followed by N-linked glycosylation [50]. Cathepsins are then
bound to the mannose-6-phosphate receptor so as to localize them in
the target lysosomes. The N-terminal peptides in pro-cathepsins are
cleaved to activate the cathepsins [51,52]. The activity of cathepsins is
regulated by several factors, such as pH, oxidation and the presence of
inhibitors. It is well known that cathepsins function optimally under
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have been shown to be active under physiological pH [53]. Human ca-
thepsins are activated under acidic conditions and are inactivated at
neutral pH and under alkaline conditions [54]. However, it was reported
that human cysteine protease cathepsin L was also inactivated at acid
pH by a ﬁrst-order process [55]. Reactive oxygen species (ROS) is a no-
torious stimulus for cathepsin release and activation [56,57]. In addition,
ROS-activated cytokines such as TNF-α, PDGF and IFN-γ also activate
and secrete cathepsins B and L in ﬁbroblast-like cells [58]. Similar results
have been reported in neonatal cardiomyocytes, suggesting the poten-
tial role of cathepsins in cardiac diseases [59]. Additionally, angiotensin
II (Ang II) is reported to enhance cathepsin gene expression in hearts
[43]. Similar to MMPs and calpains, activities of cathepsins are inhibited
by their endogenous and exogenous inhibitors. Cystatins are the natural
inhibitors for cathepsins. Cystatins are classiﬁed into three groups based
on the distinct structure, tissue/organ distribution and physiological
functions. These include steﬁns, cystatins and kininogens [60]. Cystatin
reversibly binds to cysteine cathepsins [61]. In addition to natural inhib-
itors, artiﬁcial inhibitors to cathepsins, such as E64 have been designed
for research and clinical use [62]. Among the synthetic cathepsin inhib-
itors, odanacatib, a cathepsin K inhibitor is currently under clinical trial
to treat osteoporosis [63].2.4. Caspases
Caspases are a family of acid proteases that use cysteine residues as
the catalytic tools and cleave their substrates at the aspartic acid resi-
dues [64]. This family of proteases was ﬁrst observed to be critical in
the proteolytic maturation of IL-1β [65], until several years later, a
pioneer study reported that these proteases play crucial roles in the
execution of apoptosis [66]. Following this important ﬁnding, a number
of members of the caspases family, such as caspase-1, -2, -3, -8 and -9
were identiﬁed to be crucial for apoptosis [67–73]. So far, 15 members
of the caspase family have been discovered, which are essential compo-
nents for the apoptotic machinery [74]. As reviewed before [75],
caspases (caspase-2, -8, -9 and -10) with a long pro-domain are called
initiator of apoptosis caspases or group-II caspases. Conversely, caspases
containing short pro-domains are named as executioner caspases or
group-III caspases [76–78]. Together, these two groups of caspases
play a critical role in regulating apoptosis— and are the focus of discus-
sion here. Substrate speciﬁcity of caspases has been described in great
detail in previous reviews [75]. Four main substrate pockets of caspases
named S1 to S4 have been reported. Caspases are ubiquitously
expressed in all types of cells,which are initially translated from caspase
genes as inactive pro-forms. Pro-caspases are originally synthesized as
catalytically-dormant tripartite proenzymes with a single polypeptide
chain of 32–55 kDa commonly representing 3 domains. Advanced pro-
tein structure techniques have identiﬁed N-terminal pro-domains of
pro-caspases that contain motifs called death domain superfamily,
which is essential for apoptotic signaling transduction [79,80]. Pro-
caspases are converted to their active forms by proteolytic processing
at speciﬁc aspartic acid residues under the stimulation of a number of
signals. Caspase activation occurs through autoactivation via oligomeri-
zation [81,82], death receptor or mitochondrial pathways induced
transactivation [83], as well as proteolysis by other proteases including
caspases, cathepsins, calpain and granzyme B [84,85]. The activated
caspases subsequently initiate the apoptotic cascade or directly execute
apoptosis to destroy DNA and the cell. Two classes of endogenous
caspase inhibitors including natural caspase inhibitors and dominant
negative caspases have been documented [86,87]. Natural caspase in-
hibitors are derived from a wide spectrum of viruses, such as cowpox
virus [88] and baculovirus [89]. Dominant negative caspases are the al-
ternatively splicing of the primary transcript, which are enzymatically
inactive and express as modiﬁed mRNAs or truncated proteins [86].
Peptide caspase inhibitors are synthetic peptide designed to targetspeciﬁc sequence of substrates that can be cleaved by other proteases
[90,91].
3. Role of proteases in cardiometabolic diseases
Several lines of evidence have suggested that proteases participate
in the pathogenesis of varieties of diseases, such as cancer [92], inﬂam-
mation [93,94], neurodegenerative diseases [95,96], liver diseases [97],
chronic kidney disease [98] and cardiovascular disease [99,100]. During
the recent years, our understandings of the potential mechanisms by
which proteases contribute to the development of cardiometabolic
diseases have improved substantially. With this in mind, the involve-
ments of MMP, calpain, cathepsin and caspase in cardiometabolic dis-
eases and the potential molecular mechanisms involved in the process
are reviewed below.
3.1. MMPs in cardiometabolic diseases
ECM is essential for the maintenance of structural integrity, cell an-
choring, cell–cell communication, force transmission and for mediating
cell survival/apoptosis and cardiac remodeling [101]. Interestingly,
MMPs have been shown to induce the release of growth factors an-
chored in the extracellularmatrix, consequently leading to cell prolifer-
ation, suggesting a potential mechanismbywhichMMPs induce cardiac
hypertrophy and remodeling [102]. As the major class of proteases
targeting the ECM,MMPs have been reported to be involved in the path-
ogenesis of several cardiovascular diseases associated with metabolic
syndrome [14]. In fact, each component of the metabolic syndrome
has been found to enhance MMP expression and/or activity, suggesting
a pivotal role of MMPs in the etiopathology of metabolic syndrome and
cardiometabolic disease [103–107]. The subsection below provides
highlights of the role of MMPs in some of these conditions.
3.1.1. MMPs in atherosclerosis and coronary heart disease
Atherosclerosis and coronary heart disease are the most common
cardiac disease in adults [108]. The atherosclerotic plaque is composed
of a lipid core, comprising a mixture of inﬂammatory cells, especially
foam cells and an integument of ﬁbrous cap. The ﬁbrous cap is mainly
formed from the extracellular matrix laid down by the smooth muscle
cells. Collagen and elastin are the major components for the ﬁbrous
cap. The ﬁbrous cap is prone to destruction under the proinﬂammatory
conditions, which results in the release of thrombus into circulation
leading to thrombosis [109]. Coronary artery is the main vessel to be
affected by atherosclerosis, and myocardial infarction and stroke are
the major complications of atherosclerosis [110].
Numerous studies have reported elevated levels of MMPs in athero-
sclerotic plaques. Cytokines, such as TNF-α have been reported to in-
duce MMP expression in smooth muscle cells through ERK-NF-κB
signaling pathway [111]. MMPs were also activated by mast cell prote-
ases in atherosclerotic plaques [112]. In animal models of atherosclero-
sis as well as human coronary specimens, colocalization of MMP-9 and
-3 at the edges of atherosclerotic plaque has been demonstrated [113].
An in vitro study suggests enhanced MMP-2 and -9 mRNA levels in
oxidized-low density lipoprotein (ox-LDL) loaded macrophages,
which was inhibited by aspirin [114]. Almost all the MMPs are capable
of interferingwith the atherosclerotic plaquedevelopment and stability,
which has been extensively reviewed in a recent review [115]. Interest-
ingly, serum MMP-9 concentrations have been positively correlated
to total carotid artery plaque score and instability, suggesting that
MMP-9 could serve as potential marker for atherosclerosis [116]. Pro-
inﬂammatory mediators and reactive oxygen species lead to the activa-
tion ofMMPs,which further degrade collagen and elastin toweaken the
ﬁbrous cap and cause plaque rupture. The process is accelerated by
mobilized macrophages and T cells localized in advancing zone of
atherosclerotic plaque [117]. The creation of transgenic animal models
with either overexpression or knockout of MMPs, further aided in the
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disease. One earlier study reported that MMP-1 and ApoE double
knockout mice transgenic for human MMP-1 gene in macrophages,
exhibited smaller plaques with less collagen [118]. In contrast, overex-
pression of an auto-activated MMP-9 led to high levels of plaque insta-
bility in the same mouse model [119]. Similarly, overexpression of
MMP-12 in rabbits enhanced plaque size and inﬂammation [120].
It was recently found that MMP-9 and ApoE double knockout mice
displayed reduced atherosclerotic load despite being fed with a choles-
terol rich food [121]. Similar resultswere obtainedwhen using aMMP-2
and ApoE double knockout mouse model [122]. In contrast however,
MMP-3 and ApoE double knockout mice showed increased plaque
size [123]. Elevated level of MMP-9 in subjects with coronary artery dis-
ease with unstable angina has also been reported [124]. Thus, although
the exact role of MMPs in atherosclerosis remains controversial, based
on the aforementioned studies it can be concluded that elevated levels
of MMPs, especially MMP-2 and -9 are detrimental, in that, they
enhancematrix destruction and cause inﬂammation,which possibly re-
sults in plaque rupture.
Endothelial erosion that occurs in highly stenotic, ﬁbrotic plaques
without thepresence of inﬂammation has been postulated to play a pre-
dominant role in the loss of endothelial cells, which is the other com-
mon trigger for coronary heart disease [125]. MMPs are expressed on
the endothelial cellswhich express a variety ofMMP substrates (includ-
ing urokinase-type plasminogen activator receptor and TGF-beta) and
activators such as tissue plasminogen activator [126–128]. Endothelial
MMPs are also activated by cytokines including TNFα and IL-1 [129,
130]. Furthermore, endothelial MMP-9 expression can be up-regulated
by oscillatory ﬂow through activation of c-myc [131]. The elevated
endothelial MMP expression and activation may thus contribute to the
development and progression of atherosclerosis and coronary heart
disease.
It is well known that angiogenesis, the formation of new
microvessels, occurs in atherosclerotic plaques leading to neovasculari-
zation and the growth of the lesion [132]. Although the mechanisms
involved in this process are not fully understood, MMPs, especially
MMP-2 and -9, have shown to play a pivotal role in the process of angio-
genesis. ElevatedMMP-2 and -9 were reported in arteries from subjects
with diabetic chronic kidney disease, which correlated to impaired
angiogenesis and endothelial dysfunction [133]. A recent study demon-
strated that MMP-8 plays an important role in angiogenesis as well. In
this study, Fang and coworkers demonstrated that MMP-8/apoE double
knockout mice displayed attenuated angiogenesis and smaller athero-
sclerotic plaque size compared to the apoE knockout mice, concluding
that MMP-8 triggers atherosclerotic formation, and targeting MMP-8
is as a potential therapeutic target of atherosclerosis [134]. In fact, nu-
merous angiogenic signaling pathways, such as those that are induced
by the growth factors FGF and VEGF have been shown to upregulate
MMPs via Erk, JNK and Akt activation, which further consolidate the
evidence thatMMP-associated angiogenesis contributes to the develop-
ment of atherosclerosis [135–137].
3.1.2. MMPs in obesity and insulin resistance-associated cardiac disease
Obesity, which is deﬁned as an increased body mass index
(N30 kg/m2), is an important health issue for Americans in view of its
increasing prevalence [138]. Obesity usually accompanies with insulin
resistance, which is the fundamental pathological change that predis-
poses to type 2 diabetes. Both obesity and insulin resistance are
important independent risk factors for cardiac disease [139]. Several
mechanisms contribute to obesity and/or insulin resistance-induced
cardiac disease although the exact mechanism involved is far from
clear [140]. Interestingly, elevated plasma MMP-2 and -9 levels have
been found in obese women and children [141,142], which imply that
MMPs are potentially involved in obesity-associated heart disease.
This notion received support from the evidence of an animal study
published in 2001 by Peterson and coworkers who found that theMMP-2 activity in the left ventriclewas elevated in obese, spontaneous-
ly hypertensive heart failure (SHHF) rats, which paralleled impaired
ventricular function. More importantly, pharmacological inhibition
of MMP alleviated left ventricle dysfunction and remodeling in
SHHF rats, suggesting that MMP activity contributed to left ventricle
dysfunction in obese animals [143]. Sucrose-enriched diet feeding re-
sulted in lipid accumulation accompanied by upregulation of cardiac
MMP-2, MMP-9 and TIMP-1 expression in rats, which were reversed
by L-arginine supplementation [144]. Another study showed that the
activity of MMP-7, a critical regulator of cardiac ﬁbrosis was increased
in the diabetic heart as well [145]. Conﬂicting results were however
found in a human study, inwhich authors demonstrated that abnormal-
ities of left ventricle function in premenopausal obese women were
related to the decreased plasma MMP-2 levels, possibly because the
suppressed MMP system attenuates ECM degradation [146]. Results
from an animal study further revealed that MMP-2 activity was de-
creased in a rat model that spontaneously develops diabetes mellitus.
In this study, the authors observed that angiotensin II receptor blockade
prevents left ventricular diastolic dysfunction by restoring MMP-2
activity [147]. Further research is necessary to ascertain the role of
MMPs in obesity and insulin resistance-associated cardiac disease.
3.1.3. MMPs in hypertensive heart disease
Normal systolic bloodpressure iswithin the rangeof 100–140mmHg,
whereas diastolic blood pressure is within the range of 60–90 mm Hg.
Hypertension is deﬁned as a blood pressure that is persistent at or
above 140/90mmHg. Untreated or uncontrolled hypertension is an im-
portant risk factor for cardiac disease,which is called hypertensive heart
disease. The role of MMPs has been extensively studied in hypertensive
heart disease due to the involvement of ECM in cardiac remodeling
that is commonly associated with the hypertensive heart. Elevated
MMP expression levels have been documented in hearts from different
models of hypertensive animal, including angiotensin II-induced hyper-
tension [148], pulmonary hypertension [149], renovascular hyperten-
sion [150], spontaneously hypertensive rats [151], volume overload
[152] and pressure overload-induced hypertension [153]. Studies
by using transgenic models further declare the contributions of MMP/
TIMP in hypertensive heart disease. Overexpression of MMP-1 has
been reported to correct the accumulation of cardiac ﬁbrosis, cardiac
dysfunction and remodeling in response to chronic pressure overload
[154]. Conversely, MMP-2 knockout mouse was resistant to pressure
overload-induced left ventricular hypertrophy and dysfunction [155].
MMP-7 inhibition by genetic knockout and pharmacological inhibitors
displayed attenuated hypertrophy through correction of a disintegrin
and metalloproteinase-12 (ADAM-12) overexpression [156]. Further-
more, angiotensin-converting enzyme inhibitor was shown to block
MMP activity and thus protected left ventricle from remodeling and
dysfunction [157]. Additionally, MMP-associated angiogenesis has
been documented to be crucial in the transition from compensatory
hypertrophic heart to decompensatory failing heart. In this study, in-
creased MMP-2 as well as increased angiogenic factors were observed
in hypertrophic heart, whereas an increase in MMP-9 and angiostatin
was found in failing heart [158].
3.2. Calpains in cardiometabolic diseases
As discussed under Section 2.2, calpain targets a wide spectrum of
proteins, suggesting a key role of calpain in cardiac diseases. According-
ly, the involvement of calpain in cardiometabolic diseases has beenwell
documented. The following section brieﬂy discusses the role of calpain
in various cardiometabolic diseases.
3.2.1. Calpain in atherosclerosis and coronary heart disease
It is widely accepted that calpains act in the endothelial cells and
helps maintain vascular integrity. A number of factors such as VEGF
and shear stress activate the calpain system under physiological
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GTPase [161] and lyse focal adhesion proteins [160]. Interestingly,
it has been documented that nitric oxide production is mediated by
calpain-induced proteolysis of HSP90 or PI3K/AMPK signaling cascade
[159,162]. In addition to its physiological role, calpain participates in
the pathogenesis of various diseases. An earlier study revealed that
sPLA2-modiﬁed LDL or oxidized LDL enhanced m-calpain expression
in endothelial cells on atheroma [163,164]. Activated calpain directly
cleavages VE-cadherin and thus facilitates the extravasation of inﬂam-
matory cells andmacromolecules into the vascular wall [165]. Silencing
CAPN2 by siRNA technique further conﬁrmed that knockdown of
calpain induces pro-atherogenic hyperpermeability in the murine
aorta [163]. It has been reported that calpain activity is also enhanced
in endothelial cells from lipopolysaccharide-accelerated atherosclerosis
[166]. Cytokines and inﬂammatory signals are involved into the devel-
opment of atherosclerosis. Nuclear factor-κB (NF-κB) signal, a represen-
tative inﬂammatory signal, wasmodulated by calpain via degradation of
IκB without affecting its phosphorylation [167]. Not surprisingly, NF-κB
aswell as cytokine levels in endothelial cells frompro-atherogenic aorta
in LDLr−/−mice were remarkably decreased following the administra-
tion of calpain inhibitors [163]. Macrophage-derived foam cells are hall-
mark for atherosclerosis. Activated ATP-binding cassette transporter A1
(ABCA1) in macrophages is shown to be dampened by calpain-induced
proteolysis [168]. Calpain has also been shown to interfere with choles-
terol efﬂux from macrophage through the degradation of the ATP-
binding cassette transporter G1 (ABCG1) [169]. In smooth muscle
cells, activation of calpain was reported to precede the activation of
caspase in response to degraded collagen, whereas, inhibition of calpain
was observed to reduce apoptotic response, suggesting a potential role
of calpain in atherosclerotic plaque rupture [170]. Evidence from a clin-
ical study conﬁrmed the association of calpain-10 with atherosclerosis
and coronary heart disease in human [171].
3.2.2. Calpain in obesity and insulin resistance-associated cardiac disease
CAPN10 has been identiﬁed as a diabetic gene and a number of posi-
tional cloning studies have identiﬁed that genetic variation in CAPN10
accounted for 14% of the population-attributable risk to type 2 diabetes
in Mexican Americans [172]. Several studies published subsequently,
using a wide range of ethnic populations further conﬁrmed the associa-
tion of CAPN10 with type 2 diabetes [173–178]. This suggests that
calpains may be potentially involved in insulin regulated pathway. The
ﬁrst paper in support of the role of calpain on insulin signaling pub-
lished in 1990s, demonstrated that calpain regulates the expression of
insulin receptor substrate-1 (IRS-1) [179]. A series of recent studies
strongly support this notion that calpain regulates insulin signaling
pathway. Calpain inhibitors prevented IRS-1 downregulation, while
drug-induced overload of intracellular Ca2+ could restore the sup-
pressed IRS-1 level [16]. A clinical study demonstrated that activation
of calpain was detrimental to the diabetic myocardium, and blocking
calpain activation protected heart from diabetes-associated cardiac in-
jury [180]. Nonetheless, literature regarding the contribution of calpain
in obesity, insulin resistance and associated cardiac disease is limited
warranting further studies to understand the exact nature of the role
of calpains in obesity and insulin resistance-associated cardiac disease.
3.2.3. Calpain in hypertensive heart disease
Several transcriptional factors, such as NF-κB, GATA binding protein
4 (GATA4) and nuclear factor of activated T cells (NFAT) participate in
the development of hypertension-induced cardiac hypertrophy. Inter-
estingly, calpain has been reported as a critical regulator for NF-κB,
GATA4 and NFAT, implying the possible role of calpain in cardiac hyper-
trophy [167,181,182]. Enhanced calpain activity as well as decreased
calpastatin expression was found in hearts from mice subjected to an-
giotensin II infusion [183]. In the same study, experiments performed
on transgenic mice that constitutively express calpastatin revealed
that infusion of angiotensin II failed to induce cardiac hypertrophy,although those mice did develop hypertension. Parallel to this ﬁnding,
angiotensin II-induced NF-κB over-expression was blunted by
calpastatin transgene in mice, which may represent the molecular
mechanism by which calpastatin over-expressed mice exhibited resis-
tance to hypertension-associated cardiac hypertrophy [183]. In line
with these ﬁndings, pre-administration of calpeptin, a speciﬁc calpain
inhibitor, to hypertensive β3-integrin-deﬁcient mice alleviated cardio-
myocyte apoptosis and prevented cardiac hypertrophy [184]. Another
study suggested that elevated calpain activation in hypertrophic heart
could lead to the degradation of focal adhesion kinase aswell as calcine-
urin to worsen cardiac hypertrophic response [185]. Treatment with
calpain inhibitor attenuated cardiac hypertrophy via inhibiting the
degradation of these proteins. Indeed, most substrates of calpain are po-
tentially involved in the pathogenesis of hypertensive heart disease.
However, more conclusive studies are necessary to evaluate the molec-
ular pathways by which calpains contribute to cardiac hypertrophy.
3.3. Cathepsins in cardiometabolic diseases
Studies in the recent years have implicated a role of cathepsins in the
etiopathology of cardiometabolic disease. Several cathepsins, such as
cathepsins S, K, B and L have been found to be expressed in cardiomyo-
cyte, cultured cardiac ﬁbroblasts and/or myoﬁbroblasts [59,186,187].
Although the expression of cathepsins in the heart is negligible at
basal conditions, stimulation by cytokines, angiotensin II and superox-
ide can remarkably enhance their expression [43]. The following section
provides an outline of our understanding of the role of cathepsin in
various cardiometabolic diseases.
3.3.1. Cathepsins in atherosclerosis and coronary heart disease
Cathepsins exhibit potent collagenase and elastase activity, by virtue
of which they potentially participate in the formation and rupture of
atheroma. Early studies documented that increased cathepsin activity
was associated with experimental atherosclerosis [188]. Two decades
ago, Reddy and the colleague observed that human macrophages se-
crete the active form of cathepsins S, B and L [189]. Subsequent studies
showed that cathepsin D regulates ABCA1-mediated lipid efﬂux and de-
creased levels of cathepsin D levels results in low plasma HDL-C levels
[190]. Platt and coworkers reported an increased expression of cathep-
sin K in the endothelium of human subjects with atherosclerosis [191].
Consistent with these observations, cathepsin levels were also found to
be elevated in a diet-induced animal model of atherosclerosis [192]. A
recent study investigated the relative expression of cathepsins at differ-
ent sites of atherosclerotic plaque. Increased cathepsin expression was
detected in sites prone to rupture, including macrophages bordering
the lipid core and adjacent to the ﬁbrous cap or macrophages/smooth
muscle cells in the shoulder regions [193,194]. Cathepsin L has been
shown to be the major contributor to apoptosis of the macrophages
resulting in necrotic core formation, leading to atherosclerotic plaque
instability [195]. Interestingly, one recent study showed that cathepsin
Gdeﬁciency attenuated the complexity of atherosclerotic lesions in apo-
lipoprotein E-deﬁcient mice via dampening apoptosis [196]. Cathepsin
S, on the other hand, improves ﬁbrous cap stabilization, and helps
monocyte adhesion andmigration in an in vitro system [197]. Cathepsin
K levels were found positively correlated to the percent plaque volumes
and negatively correlated to percent ﬁbrous volumes. Additionally,
cathepsin K blood levels have been claimed to be an independent
predictor of coronary heart disease [198]. Similarly, serum cathepsin L
contents were signiﬁcantly increased in patients with coronary heart
disease [199,200]. However, Mirzaii-Dizgah and coworkers failed to ob-
serve any changes in serum and salivary cathepsin L levels in subjects
with coronary heart disease [201]. Cystatin c, an endogenous inhibitor
of cathepsin, has also been implicated in the development of coronary
heart disease in a human study. The mutant haplotype of cystatin c
gene was related to higher average number of stenosis per coronary
artery segment [202]. Collectively these studies show that cathepsins
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disease. However different cathepsins may have different roles in the
pathogenesis — some of them being detrimental whereas some others
being protective. Targeting cathepsins may thus represent an attractive
strategy to treat atherosclerosis and coronary heart disease.
3.3.2. Cathepsins in obesity and insulin resistance-associated cardiac
disease
In the year 2003, cathepsin K was identiﬁed as a novel marker of
adiposity in white adipose tissue owing to its high levels of expression
in white adipose tissue in the db/dbmice [203]. Moreover, the expres-
sion of the transcription factors involved in the induction of cathepsin
K was also elevated in the white adipose tissue from obese mice [203].
Subsequent studies ascertained the role of cathepsin K in adipocyte dif-
ferentiation. Inhibition of cathepsin K by either pharmacological inhibi-
tor or genetic ablationwas sufﬁcient to reverse adipocyte differentiation
and lipid accumulation in response to high-fat diet feeding [204,205].
Cathepsin K inhibition prevented high-fat diet or leptin deﬁciency-
induced obesity as well as elevated serum glucose and insulin levels
by degrading ﬁbronectin [206]. Degradation of type I collagen has also
been proposed as a potential mechanism by which cathepsin K partici-
pates in adipogenesis during the early differentiation phases [207].
Cathepsin S is another extensively studied cathepsin in terms of its
role in the obesity. A number of studies have reported elevated levels
of cathepsin S in adipose tissues from both human and animal models
[208–210]. Interestingly, weight loss inmorbidly obesewomen resulted
in reduced expression of cathepsin S in the adipose tissue and lower
circulating levels of this protease [211]. Recently, cathepsin D was also
shown to be up-regulated in obese mouse and human adipose tissue
[212]. In addition, activated cathepsin D associated with adipocyte
hypertrophy triggered the activation of proapoptotic proteins [213].
Expression levels of cathepsin L in themuscle have been shown to be
elevated in glucose intolerant mice [214]. In the skeletal muscle of dia-
betic subjects, reduced insulin-stimulated cathepsin L gene expression
was also reported in this paper, suggesting that impaired cathepsin L ex-
pression is secondary to impaired glucose metabolism [214]. Cathepsin
S levels strongly correlate with insulin resistance as reported by Jobs
and coworkers, who in their study showed that subjects with higher
cathepsin S levels had decreased insulin sensitivity and higher risk to
develop type 2 diabetes [215]. This ﬁnding was further supported by a
study from Chen and colleagues who showed a correlation between
serum cathepsin S and insulin resistance, in type 2 diabetic subjects
[216].
In our lab, we investigated the role of cathepsin K in obesity-
associated cardiac dysfunction. We found that genetic ablation of ca-
thepsin K in mice protected hearts from high-fat diet feeding-induced
geometric and functional impairment, as evidenced by recovered frac-
tional shortening as well as peak shortening of single cardiomyocytes.
Mechanistically, insulin signaling pathway was dampened in the heart
from high-fat diet feed mice, which was rescued by cathepsin K knock-
out. Moreover, activated apoptosis in mouse heart consequent to high-
fat diet feeding was attenuated by cathepsin K knockout [187]. These
studies substantiate the notion that cathepsin K participates in
obesity-associated heart disease and targeting cathepsin K maybe a
promising approach to counter obesity-associated complications in
the heart.
3.3.3. Cathepsins in hypertensive heart disease
The early report linking cathepsin to hypertension was from a study
by Saito and coworkers, wherein an increased cathepsin level in the
serum of spontaneously hypertensive rats was observed [217]. A study
published in the following year further by Wildenthal and coworkers
conﬁrmed the role of this lysosomal enzyme in the development of
hypertension-induced cardiac hypertrophy [218], whichwas substanti-
ated by another study by Rozek et al. [219]. Impaired cathepsin B activ-
ity was displayed in hypertensive heart, which was reversed by thetreatment with ACE inhibitor. Additionally, the ACE inhibitor alleviated
hypertension-associated cardiac hypertrophy in rats [220]. Cheng and
coworkers investigated the role of cathepsin in hypertension-induced
heart failure in rat [59]. They identiﬁed cathepsin S as the predominant
cathepsin that is elevated in the failing heart. Furthermore, the expres-
sion and activity of cathepsin S were induced by IL-1β in cultured neo-
natal cardiomyocytes, suggesting that inﬂammatory mediators activate
cathepsin S. A follow-up study from same group reported that superox-
ide anions activate cathepsin, which in turn triggersmyocardial remod-
eling [43]. Blocking angiotensin II type 1 receptor attenuatedmyocardial
remodeling and dysfunction via blunting superoxide-dependent induc-
tion of cathepsin. Additionally, the involvement of cathepsin G in the
alternative pathways of angiotensin II biosynthesis makes cathepsin G
a potential mediator in the development of hypertensive heart disease,
although studies to this effect are lacking [221].
Despite the documented role of cathepsins in the pathophysiology of
hypertensive heart disease, the underlying molecular mechanisms re-
main elusive. Most effects attributed to cathepsins in hypertensive
heart disease are linked to the degradation of collagen or elastin. How-
ever, recent studies have suggested that cathepsins are involved in the
crosstalk with several signaling pathways, which may contribute to
their observed effects. The Akt/GSK3β pathways have been extensively
studied in cardiac hypertrophy because of their effects on inﬂammation,
ﬁbrosis as well as apoptosis. By using a cathepsin L overexpressed
mouse model, Tang and coworkers showed that cathepsin L protects
against hypertension-induced cardiac hypertrophy via inactivation of
the Akt/GSK3β signaling pathway [222]. In contrast, cathepsin L knock-
out inmicewas shown to accentuate pressure overload-induced cardiac
hypertrophy [223]. Impaired lysosomal protein degradation, increased
sarcomere-associated protein aggregation, increased ubiquitin–protea-
some system as well as altered endoplasmic reticulum homeostasis
were found in hypertensive cathepsin L knockout mice, all of which re-
sulted in the worsening of cardiac function and cardiac remodeling in
response to pressure overload. We evaluated the role of cathepsin K
knockout in mice subjected to pressure overload-induced cardiac hy-
pertrophy [224]. Our results support the notion that cathepsin K knock-
out in mice prevents the development of cardiac hypertrophy and
contractile dysfunction. Moreover, the stimulation of the mTOR and
Erk signaling pathways which were induced in hypertrophic heart,
was blunted by cathepsin K knockout and in cultured cardiomyocytes
subjected to siRNA mediated silencing of cathepsin K. Furthermore,
plasmid-mediated overexpression of cathepsin K in the cultured
cardiomyocytes triggered cardiomyocyte hypertrophy, which was
blocked by mTOR and Erk inhibitors. Collectively, our data suggest the
important role of cathepsin K in cardiac hypertrophy induced by
hypertension.
3.4. Caspases in cardiometabolic diseases
Caspases are essential players in the apoptotic cascade, playing a
pivotal role in the initiation and execution of apoptosis. Volumes of
literature have reported the involvement of apoptosis in cardiac disease,
including cardiometabolic disease and a detailed discussion is beyond
the scope of this review. The role of caspase in cardiometabolic disease
will be the focus here.
3.4.1. Caspases in atherosclerosis and coronary heart disease
Macrophages are the most abundant inﬂammatory cells in athero-
sclerotic plaque. Macrophage-derived foam cells with lipid core repre-
sent the major component of the atherosclerotic plaque. Fas or other
death receptor triggered apoptosis has been proposed to contribute to
plaque macrophage death and even plaque development [225,226].
Importantly, expression of c-FLIP, a dominant-negative inhibitor of
caspase-8, has been reported to protect plaque macrophages from
apoptotic cell death [227]. Role of caspase in macrophage apoptosis
has been extensively reviewed in a previous literature [228]. Oxidized
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229]. Oxidized LDL-induced apoptosis involves both the death receptor
and mitochondrial apoptotic pathways. Caspase cascade is in turn acti-
vated, which triggers apoptosis [230]. Besides macrophage, vascular
cells such as endothelial cells and smoothmuscle cells undergo apopto-
sis in atherosclerosis plaque as well. The role of apoptosis in plaque en-
dothelial cells and smooth muscle cells has been reviewed elaborately
in previous reports [231,232].
3.4.2. Caspases in obesity and insulin resistance-associated cardiac disease
Lipoapoptosis has been observed in obesity and type 2 diabetes,
which is an important feature that contributes to obesity-associated
cardiac dysfunction. Accumulated unoxidized fatty acids in obese sub-
jects trigger toxic pathways, such as ceramide pathway to initiate apo-
ptosis in cardiomyocytes [233]. Increased cardiomyocyte fatty acid
oxidation as well as inhibition of glucose uptake have been reported
to induce apoptosis and result in dilated cardiomyopathy in mice ex-
pressing glycosylated-inositol (GPI)-anchored human lipoprotein lipase
(hLpLGPI) [234]. Studies from our group have documented the involve-
ment of caspase activation and apoptosis in cardiac dysfunction in re-
sponse to high-fat diet feeding [187,235]. Additionally, in genetically
obesemice, enhanced apoptotic response in cardiomyocytewas accom-
panied by increased DNA damage and decreased survival rate [236].
Elevated cardiac Fas receptor-dependent apoptotic pathway has been
observed in obese Zucker rats [237]. Increased protein levels of Fas
ligand, Fas death receptors, Fas-associated death domain were signiﬁ-
cantly up-regulated in obese rat hearts, which was paralleled with
enhanced caspase-8 and -3 activities, suggesting the involvement of
Fas receptor-dependent apoptosis in obesity-associated heart disease
[237]. Interestingly, another study from the same group reported acti-
vated cardiac mitochondrial-dependent apoptotic pathway in obese
Zucker rats. Increased Bcl-2/adenovirus E1B 19 kDa interacting protein
(BNIP3), Bad expression as well as cytochrome c release were observed
in hearts from obese rats. A reciprocal suppression of the antiapoptotic
Bcl2 protein level was observed. Moreover, an increase in the expres-
sion of activated caspase-9 and -3was reported, suggesting the involve-
ment of mitochondrial-dependent apoptotic pathway in obesity-
associated heart disease [238]. A follow-up study further conﬁrmed
the effect of mitochondrial apoptotic pathway in obesity-associated
cardiac disease. Furthermore, aerobic exercise training was effective in
blocking cardiac mitochondrial apoptotic signaling and rescuing cardiac
dysfunction [239].More importantly, reduction in bodymass resulted in
attenuated apoptosis, oxidative stress and inﬂammation,which rescued
left ventricular remodeling as well as heart dysfunction in obese
mice [240]. Cardiac remodeling caused by a high-carbohydrate, high-
fat diet-induced metabolic change was alleviated by rutin via its
antiapoptotic properties [241]. Collectively, the aforementioned studies
provide strong evidence in support of the relationship between caspase-
induced apoptosis and obesity/insulin resistance-induced heart disease.
3.4.3. Caspase in hypertensive heart disease
Ravassa and colleagues reported the contribution of apoptosis in an-
giotensin II-induced ventricular cardiomyocyte dysfunction in the spon-
taneously hypertensive rats [242]. This ﬁnding was supported by the
studies from the labs of Lopez-Farre and [243] and deBlois group
[244]. Interestingly, the elevated apoptosis in hypertrophic hearts of
spontaneously hypertensive rats was attenuated by exercise training
[245]. Moreover, cardiomyocyte apoptosis was triggered in the failing
hearts of hypertensive human subjects. On the other hand, the expres-
sion of gp130, a protein preventing cardiomyocyte apoptosis, was de-
creased in the failing heart of hypertensive patients. There was a
negative correlation between gp130 and cardiomyocyte apoptosis in
hypertensive patients that develop heart failure [246]. Endoplasmic re-
ticulum (ER) stress-induced apoptosiswas reported in the hypertensive
heart in high-salt diet fed Dahl salt-sensitive rats. Caspase-12 has been
shown to be involved in the ER stress-associated cardiomyocyteapoptosis in hypertensive heart [247]. Interestingly, caspase-3 and
calpain activities were elevated at the same time in the pressure
overload-induced hypertrophic heart, whereas calpain inhibitor could
block caspase-3 activation and prevent cardiac dysfunction. However,
caspase inhibitor was not beneﬁcial to cardiac function in the pressure
overload model. Based on these ﬁndings the authors concluded that
calpain may be the key mediator of cardiomyocyte death, although ap-
optosis cascademay be involved in the progression of end-stage hyper-
trophy to heart failure [34]. The exact role of caspase and apoptosis in
hypertensive heart disease remains unclear although the activation of
apoptosis under this condition is deﬁnite.
4. Potential clinical application of proteases
Due to the important role of proteases in ECM degradation, intracel-
lular protein degradation and participation in a variety of singling path-
ways, it is reasonable to expect the possibility of harnessing proteases
and their endogenous and synthetic inhibitors in the diagnosis or treat-
ment of cardiometabolic diseases. MMPs, cathepsins and caspases have
been suggested as potential diagnostic markers for the detection and
prognosis of cardiometabolic disease. Recent studies have shown that
elevated levels of serum MMP-9 was found in atherosclerotic carotid
artery, and is related to the plaque vulnerability, suggesting that cathep-
sins can also be potential markers of cardiovascular disease [248]. In an-
other study, Shirakabe and coworkers investigated the change of serum
MMP-2 levels in subjects with acute heart failure before and after treat-
ment and its relationship to clinical prognosis was investigated. Follow-
ing treatment for acute heart failure, thepatients haddecreased levels of
MMP-2, indicating that prognosis of heart failure was markedly better
among the patients with altered MMP-2 levels [249]. Gene polymor-
phism of MMP-9 was found to increase the risk of clinical events in
coronary heart disease patients. Human subjects with coronary artery
disease exhibiting IL-18+ 183 AA/MMP-9-1562 CT/TT combined geno-
types were shown to have a higher risk of clinical events [250]. In
contrast, patients with 6A-1171-G-519 haplotype had a reduced risk
of clinical events [251], suggesting that genotyping forMMPmay repre-
sent a diagnostic tool for cardiac health. Cathepsins have also been sug-
gested as potential biomarkers for cardiometabolic diseases [200].
Serum cathepsin L levels were higher in patients with acute myocardial
infarction compared to thosewith unstable angina pectoris. Additional-
ly, serum cathepsin L levels were positively related to number of coro-
nary branch luminal narrowing and Gensini scores. Furthermore,
cathepsin L levels have been negatively correlated to high-density lipo-
protein and apolipoprotein, suggesting the potential diagnostic value of
serum cathepsin L levels in coronary heart disease [200]. Cystatin C, the
endogenous inhibitor of cathepsin, has also received attention as a bio-
marker for cardiometabolic diseases, including atherosclerosis [252],
heart failure [253] and hypertensive cardiac hypertrophy [254]. As the
direct executioner of apoptosis, caspases have also been evaluated as a
potential biomarker of cardiometabolic diseases. Elevated serum
caspase-1 content was observed in patients with acute angina [255].
Circulating caspase-3 p17 level has also been identiﬁed as a potential
biomarker for cardiovascular disease [256].
During the past decade, several pharmaceutical companies have
been engaged in designing and developing new drugs to target prote-
ases for the treatment of cardiometabolic diseases. TwoMMP inhibitors,
KB-R7785 from Kanebo KK Company and SC-44463 from Pﬁzer are
beingdeveloped for the treatment of cardiovascular disease [257]. Addi-
tionally, somewidely used drugs like doxycycline has been tested for its
efﬁcacy in the treatment of coronary heart disease, by virtue of its effect
onMMP [258]. Among the cathepsin family, pharmacological inhibition
of cathepsin K has garnered the most interest because of its signiﬁcant
role in bone resorption. Currently, there are three cathepsin K inhibitors
under clinical trial for treatment of osteoporosis. One such cathepsin K
inhibitor odanacatib, which is effective and without major side effects
(following a 5-year trial), is currently under phase III clinical trials
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evidenced by our lab and that of others, we can speculate the potential
application of cathepsin K speciﬁc inhibitors in treating cardiovascular
disease. Various caspase inhibitors have been designed to target a
wide spectrum of diseases. Among the caspase inhibitors, pan-caspase
inhibitors, IDN-6734 and MX1013 have been tested [260].
5. Where are we in our understanding of the role of proteases in
cardiometabolic disorders?
Although there are numerous proteases that have been identiﬁed
the key proteases with demonstrated role in cardiometabolic diseases
include the MMPs, calpains, cathepsins and caspases and their endoge-
nous activators and inhibitors. There are a number of subtypes within
these proteases, some of which have similar or opposing actions sug-
gesting redundancy and counterregulatory functions. Despite growing
evidence supporting a functional association between proteases and
cardiometabolic diseases, it is yet unclear if the upregulation of protease
activity represents a cause or consequence (or both) of cardiometabolic
disorders. It is likely that inﬂammatory mediators such as reactive
oxygen species and cytokines activate proteases which can lead
to proteolysis of substrates involved in key pathways regulating a
variety of cardiometabolic functions. It is also likely that activated
proteases upregulate inﬂammatory mediators resulting in a viciousFig. 1. Role of proteases in cardiometabolic disease. Proteases (MMP, calpain, cathepsin and casp
in response to elevated ROS, cytokines and hormones contributing to the pathogenesis of card
nuclear factor-κB. PI3K: phosphoinositide 3-kinase. AMPK: AMP-activated protein kinase. HSPcycle. Thus, the emerging consensus is that proteases play a critical
role in cardiometabolic disease and targeting proteases may represent
an important therapeutic strategy.
The proteases discussed above have all been strongly implicated in
the progression of diabetic cardiac disease and heart failure. Among
the proteases described above MMPs have been extensively studied
for their role in diabetes induced cardiac remodeling and dysfunction.
MMPs play a critical role in the cardiac remodeling event which is char-
acterized by synthesis and degradation of extracellular matrix. Thus for
MMPs, the etiopathology of cardiometabolic diseases may be attributed
to their traditional proteolytic processing of signaling molecules.
Whereas targeting of MMP activation is therefore a potential clinical
strategy to treat cardiometabolic disease, altering TIMP may also serve
as an important strategy to counterbalance the effects of MMP. On the
other hand, being a calcium-activated protease calpain plays a major
role in regulating calcium-regulated cellular process such as cardiac
contractility, hypertrophy and apoptosis. However, calpains have also
been shown to be important for maintaining protein homeostasis in
the cardiac cells, and therefore a deﬁciency of calpain may also prove
to be detrimental. This dichotomy suggests that calpains serve a regula-
tory role; whereas excessive calpain activity needs to be curbed, low
levels of calpain activity may have to be boosted. Further studies are
necessary to distinguish these diverse roles of calpain and to ascertain
conditions wherein one strategy supersedes another. At the molecularase) affect ECM remodeling and participate in a variety of intracellular signaling pathways
iometabolic diseases. MMP: matrix metalloproteinase. ECM: extracellular matrix. NF-κB:
90: heat shock protein 90. mTOR: mammalian target of rapamycin.
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via the activation of NF-κB and the tumor TGF-beta signaling pathways.
Calpains also play a critical role in cell death via activating the apoptosis
pathway and/or proteolytic degradation of molecules involved in the
apoptotic pathway. As discussed above, variation in calpain-10 gene
has been shown to be associated with diabetes. However, understand-
ing the implication of this genetic variation in cardiometabolic disease
is amatter of great interest. Cathepsins on the other hand are recent en-
trants in the ﬁeld. Among the cathepsins, the cysteinyl cathepsins that
localize in the endosomes or lysosomes are thought to play a major
role in cardiometabolic disease as lysosomal membrane instability
caused by a variety of cellular stressors can lead to the release of these
proteases. Although these proteases are optimally active in the acidic
environment some of them may retain their activity in the neutral
cytoplasmic or extracellular environment and mediate their potent
elastolytic or collagenolytic activity. Caspases on the other hand have
been shown to mediate apoptosis. MMPs, calpains and cathepsins can
cause proteolytic activation of caspases leading to cell cellular apoptosis
suggesting a cross-talk between different proteases.
Future research should be directed at studying the global changes in
these proteases to address the following questions: i) Is there a redun-
dancy and counter-regulation among the proteases; and among prote-
ases and their respective inhibitors? ii) In addition to their proteolytic
activities are non-traditional mechanisms (such as autophagy),
involved in mediating the activities attributed to these proteases?
iii) What is the extent of cross-talk between these proteases? and
iv)What are the upstream regulators and downstream effectors of pro-
teases, and can any of these be used as biomarkers of cardiometabolic
syndrome and/or targets for treatment? Investigating these and other
relevant questions would provide useful insights to our growing under-
standing of the role of proteases in cardiometabolic disease.
6. Conclusion
Emerging studies suggest a strong role of proteases especially
MMPs, calpain, cathepsins and caspases in the development of cardio-
metabolic diseases, including atherosclerosis/coronary heart disease,
obesity/insulin resistance-associated heart disease and hypertensive
heart disease. Targeting these proteases would therefore represent a
novel therapeutic approach for treating or controlling cardiometabolic
diseases. Studies in human and animalmodels show that the expression
of MMPs, calpain, cathepsins and caspases under cardiometabolic con-
ditions is regulated by a variety of stimulants such as cytokines, ROS
and angiotensin II. Traditionally, the activated proteases either degrade
ECM or intracellular proteins to contribute to the pathogenesis of car-
diometabolic diseases. Recently however, the nontraditional effects of
protease have been elucidated. Proteases have been shown to regulate
signaling cascades such as the Akt and mTOR signaling pathways.
These novel insights not only add to our growing understanding of the
role of proteases in cardiometabolic diseases but also would provide
novel avenues of treatment of this disease (Fig. 1). More studies are
warranted to understand the cross-talk between proteases and cellular
signaling pathways. Such studies, together with already published
work would provide a strong rationale for clinical trials which would
allow the harnessing of protease inhibitors in treating cardiometabolic
diseases.
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